TrialCancer2018

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

David Schiff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.